Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-LNC1004 in RAIR-DTC
NCT06898437Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-DOTA-EB-FAPI in differentiated thyroid cancer (DTC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Response Rate at 24 months. Started Mar 2025; status: recruiting.
02
Drugs
177Lu-DOTA-EB-FAPI
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT06898437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898437.